The estimated Net Worth of Jakob Loven is at least 7.09 百万$ dollars as of 16 April 2021. Jakob Loven owns over 68,717 units of Kronos Bio stock worth over 1,249,345$ and over the last 6 years Jakob sold KRON stock worth over 5,844,628$.
Sign up
Jakob Loven KRON stock SEC Form 4 insiders trading
Jakob has made over 4 trades of the Kronos Bio stock since 2018, according to the Form 4 filled with the SEC. Most recently Jakob sold 68,717 units of KRON stock worth 1,418,319$ on 16 April 2021.
The largest trade Jakob's ever made was buying 312,500 units of Kronos Bio stock on 1 October 2018 worth over 5,000,000$. On average, Jakob trades about 79,472 units every 133 days since 2018. As of 16 April 2021 Jakob still owns at least 1,301,537 units of Kronos Bio stock.
You can see the complete history of Jakob Loven stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
What's Jakob Loven's mailing address?
Jakob's mailing address filed with the SEC is C/O KRONOS BIO, INC., 1300 SO. EL CAMINO REAL, SUITE 300, SAN MATEO, CA, 94402.
Insiders trading at Kronos Bio
Over the last 4 years, insiders at Kronos Bio have traded over 6,434,800$ worth of Kronos Bio stock and bought 7,151,111 units worth 30,320,233$ . The most active insiders traders include John C Martin、Norbert W Bischofberger、Arie Belldegrun. On average, Kronos Bio executives and independent directors trade stock every 33 days with the average trade being worth of 178,391$. The most recent stock trade was executed by Norbert W Bischofberger on 27 June 2024, trading 615,518 units of KRON stock currently worth 732,466$.
What does Kronos Bio do?
Kronos Bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of novel cancer therapeutics. The company's product engine focuses on dysregulated transcription factors and the transcriptional regulatory networks that drive oncogenic activity. Its lead product candidate is entospletinib (ENTO), is an orally administered, selective spleen tyrosine kinase inhibitor for acute myeloid leukemia patients. The company planned registrational phase 3 clinical trial of ENTO in combination with induction chemotherapy in acute myeloid leukemia patients with NPM1 mutations. It is also developing KB-0742, an orally bioavailable inhibitor of cyclin dependent kinase 9 for the treatment of MYC-amplified solid tumors, which is in phase 1/2 clinical trial. The company was incorporated in 2017 and is headquartered in San Mateo, California.
What does Kronos Bio's logo look like?
Complete history of Jakob Loven stock trades at Arvinas Inc、Kronos Bio
Kronos Bio executives and stock owners
Kronos Bio executives and other stock owners filed with the SEC include:
-
Jorge F. DiMartino M.D., Ph.D.,
Chief Medical Officer & Exec. VP of Clinical Devel. -
Dr. Norbert W. Bischofberger Ph.D.,
Pres, CEO & Director -
Dr. Yasir B. Al-Wakeel BCh, BM, MA,
CFO & Head of Corp. Devel. -
Dr. Norbert W. Bischofberger,
Pres, CEO & Director -
David M. Tanen J.D.,
Sec. & Director -
Joshua A. Kazam,
Co-Founder & Director -
Marni Kottle,
Sr. VP of Corp. Communications & Investor Relations -
Dr. Christopher Dinsmore Ph.D.,
Chief Scientific Officer -
Barbara A. Kosacz J.D.,
COO & Gen. Counsel -
Charles Lin Ph.D.,
Sr. VP of Biology -
Dr. Pasit Phiasivongsa Ph.D.,
Sr. VP of Pharmaceutical Devel. -
Stephanie Yao,
Exec. Director of Investor Relations & Corp. Communications -
Dr. Christopher Dinsmore,
Chief Scientific Officer -
Barbara A. Kosacz,
COO & Gen. Counsel -
Dr. Yasir B. Al-Wakeel,
CFO & Head of Corp. Devel. -
Norbert W Bischofberger,
PRESIDENT & CEO -
Barbara Kosacz,
COO & General Counsel -
Yasir B. Al Wakeel,
Chief Financial Officer -
Christopher Dinsmore,
Chief Scientific Officer -
Norbert W. & Inger A. Revoc...,
10% owner -
Arie Belldegrun,
-
Rebecka Belldegrun,
Director -
Jakob Loven,
Director -
John C Martin,
Director -
Otello Stampacchia,
Director -
Fund V, L.P.Omega Fund V Gp...,
-
Jorge Di Martino,
Chief Medical Officer & VP -
Backer Marianne De,
Director -
Roshawn A. Blunt,
-
Roger D Dansey,
-
David M Tanen,
-
Joshua A Kazam,
-
Allison Frisbee,
SR VP, CORP OPERATIONS & LEGAL -
Charles Y Lin,
SR VP, RESEARCH & DEVELOPMENT -
Elizabeth A Olek,
SR VP, CLINICAL SCIENCE -
Taiyin Yang,
-
Elena Ridloff,
-
Katherine V Stultz,
-
Deborah Knobelman,
Chief Financial Officer